NIKE, Inc. Announces Planned CFO Transition —
NIKE, Inc. has announced a leadership change, appointing Pfizer executive David Denton as its new Chief Financial Officer.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
NIKE, Inc. is initiating a planned transition of its Chief Financial Officer position. The company has selected David Denton, currently an executive at Pfizer, to step into the role.
Reports highlight that this change occurs while the company navigates a slow turnaround effort. Future developments will involve the formal commencement of Denton's tenure as CFO.
Coverage does not yet specify the exact date the transition will be completed.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 1h ago.
Quick answers
Who is the new CFO of Nike?
David Denton, a Pfizer executive, has been named as the incoming CFO.
What is the context of this appointment?
The transition is described by reports as occurring amid a slow turnaround effort at the company.
When will the transition take place?
Coverage does not yet specify a date for the transition.
Coverage (6)
- NIKE, Inc. Announces Planned CFO Transition — About Nike · 22h ago
- Nike Discloses CFO Transition WWD · 22h ago
- Nike names Pfizer executive David Denton as CFO amid slow turnaround effort Reuters · 22h ago
- Nike Hires Pfizer's Denton to Take Over for Departing CFO Bloomberg.com · 22h ago
- Nike Names Pfizer’s Denton as Next CFO WSJ · 22h ago
- NIKE, Inc. Announces Planned CFO Transition — About Nike · 22h ago
Topics
Related trends
MIO: Memories In Orbit Developer Douze Dixièmes Shutting Down
The independent game development studio Douze Dixièmes, creator of the 2026 title MIO: Memories in Orbit, is ceasing operations.
US announces $17.5 billion in loans for nuclear power supply chain
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
SpaceX stock dips below $150 before rebounding
SpaceX shares see significant volatility in today's trading, dipping below $150 before a mid-day recovery.
Closely watched Pfizer lung cancer drug falls short in clinical trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Tech giant Oracle cuts 21,000 jobs as it embraces AI
Oracle is cutting 21,000 jobs as the company pivots resources toward artificial intelligence investments.